

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA Ravulizumab for treating paroxysmal nocturnal haemoglobinuria

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Final appraisal determination

(when no ACD was issued)

- | |
|---|
| 1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how? |
|---|

At the scoping stage it was noted people under the age of 18 and pregnant people were excluded from the main trials of ravulizumab. It was highlighted that age and pregnancy are protected characteristics which need to be considered. It was also noted that people with paroxysmal nocturnal haemoglobinuria are classified as disabled, and disability is another protected characteristic. Ravulizumab is given less often than eculizumab and that this may be beneficial for vulnerable patients, such as older people.

The committee considered issues relating to people included within the marketing authorisation. People under the age of 18 are not included within the marketing authorisation. For pregnant people the use of ravulizumab may be considered following an assessment of the risks and benefits.

- | |
|--|
| 2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these? |
|--|

No equality issues were raised

3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these?

No equality issues were identified

4. Do the recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No

5. Is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

Not applicable

7. Have the committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?

Section 3.12 of FAD

Approved by Associate Director (name): Jasdeep Hayre

Date: 29 March 2021

Technology appraisals: Guidance development

Equality impact assessment for the single technology appraisal of ravulizumab for treating paroxysmal nocturnal haemoglobinuria

Issue date: April 2021